Sherene Loi
Showed that immune cells inside breast tumours predict outcome, the basis for de-escalating chemotherapy in TNBC.
Sherene Loi's work on tumour-infiltrating lymphocytes established TILs as a prognostic and predictive biomarker in breast cancer, underpinning current efforts to spare stage I TNBC patients chemotherapy; she leads immunotherapy trials and the International Immuno-Oncology Biomarker Working Group.
| Title | Journal | Year |
|---|---|---|
| Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers | Journal of Clinical Oncology | 2019 |
Pages like this
not linked directly; found by shared links- PersonJoseph Trapani
Shares Peter MacCallum Cancer Centre, Immune checkpoint inhibitors.
- PersonAnn H. Partridge
Shares Breast Cancer Research Foundation, HR-positive / HER2-negative breast cancer.
- IdeaNeoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC
Shares KEYNOTE-522, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors.
- PersonSarah-Jane Dawson
Shares Peter MacCallum Cancer Centre, HR-positive / HER2-negative breast cancer.
- IdeaTIL-based omission of chemotherapy in stage I TNBC
Shares Tumour-infiltrating lymphocytes (TILs), Triple-negative breast cancer (TNBC).
- InstitutionCancer Council Australia
- PersonSara A. Hurvitz
Shares NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonCarsten Denkert
Shares Tumour-infiltrating lymphocytes (TILs), Triple-negative breast cancer (TNBC).